Galapagos NV (GLPG.AS)
EUR 25.7
(0.78%)
EUR 25.7
(0.78%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 4.94 Million EUR | -66.35% |
| 2022 | 14.69 Million EUR | -25.25% |
| 2021 | 19.65 Million EUR | -14.67% |
| 2020 | 23.03 Million EUR | 17.78% |
| 2019 | 19.55 Million EUR | 0.0% |
| 2018 | - EUR | 0.0% |
| 2017 | - EUR | -100.0% |
| 2016 | 9000.00 EUR | -85.71% |
| 2015 | 63 Thousand EUR | -45.22% |
| 2014 | 115 Thousand EUR | -31.14% |
| 2013 | 167 Thousand EUR | 1.21% |
| 2012 | 165 Thousand EUR | -63.41% |
| 2011 | 451 Thousand EUR | -47.98% |
| 2010 | 867 Thousand EUR | -10.06% |
| 2009 | 964 Thousand EUR | -16.61% |
| 2008 | 1.15 Million EUR | -33.83% |
| 2007 | 1.74 Million EUR | -61.98% |
| 2006 | 4.59 Million EUR | 0.0% |
| 2005 | - EUR | 0.0% |
| 2004 | - EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 3.83 Million EUR | 0.0% |
| 2024 Q3 | 7.24 Million EUR | 0.0% |
| 2024 Q2 | 6.74 Million EUR | 0.0% |
| 2023 Q3 | 8.46 Million EUR | -8.0% |
| 2023 Q2 | 9.2 Million EUR | -9.91% |
| 2023 Q1 | 10.21 Million EUR | -30.46% |
| 2023 FY | 4.94 Million EUR | -66.35% |
| 2023 Q4 | 4.94 Million EUR | -41.62% |
| 2022 FY | 14.69 Million EUR | -25.25% |
| 2022 Q1 | 18.28 Million EUR | -6.95% |
| 2022 Q2 | 16.87 Million EUR | -7.73% |
| 2022 Q4 | 14.69 Million EUR | -6.77% |
| 2022 Q3 | 15.75 Million EUR | -6.61% |
| 2021 Q1 | 22.17 Million EUR | -3.73% |
| 2021 Q2 | 21.42 Million EUR | -3.37% |
| 2021 Q4 | 19.65 Million EUR | 2.76% |
| 2021 Q3 | 19.12 Million EUR | -10.74% |
| 2021 FY | 19.65 Million EUR | -14.67% |
| 2020 Q2 | 20.38 Million EUR | 8.1% |
| 2020 Q3 | 21.95 Million EUR | 7.68% |
| 2020 Q4 | 23.03 Million EUR | 4.94% |
| 2020 FY | 23.03 Million EUR | 17.78% |
| 2020 Q1 | 18.85 Million EUR | -3.59% |
| 2019 Q4 | 19.55 Million EUR | -0.52% |
| 2019 FY | 19.55 Million EUR | 0.0% |
| 2019 Q1 | 20.4 Million EUR | 0.0% |
| 2019 Q3 | 19.66 Million EUR | -3.89% |
| 2019 Q2 | 20.45 Million EUR | 0.24% |
| 2018 Q1 | - EUR | 0.0% |
| 2018 Q3 | - EUR | 0.0% |
| 2018 FY | - EUR | 0.0% |
| 2018 Q4 | - EUR | 0.0% |
| 2018 Q2 | - EUR | 0.0% |
| 2017 FY | - EUR | -100.0% |
| 2017 Q4 | - EUR | 0.0% |
| 2017 Q3 | - EUR | 0.0% |
| 2017 Q2 | - EUR | 0.0% |
| 2017 Q1 | - EUR | -100.0% |
| 2016 Q4 | 9000.00 EUR | -60.87% |
| 2016 FY | 9000.00 EUR | -85.71% |
| 2016 Q1 | 50 Thousand EUR | -20.63% |
| 2016 Q2 | 37 Thousand EUR | -26.0% |
| 2016 Q3 | 23 Thousand EUR | -37.84% |
| 2015 Q1 | - EUR | -100.0% |
| 2015 Q2 | 89 Thousand EUR | 0.0% |
| 2015 FY | 63 Thousand EUR | -45.22% |
| 2015 Q4 | 63 Thousand EUR | -17.11% |
| 2015 Q3 | 76 Thousand EUR | -14.61% |
| 2014 Q4 | 115 Thousand EUR | 0.0% |
| 2014 Q2 | 140 Thousand EUR | 0.0% |
| 2014 Q1 | 140 Thousand EUR | -16.17% |
| 2014 FY | 115 Thousand EUR | -31.14% |
| 2013 FY | 167 Thousand EUR | 1.21% |
| 2013 Q3 | 167 Thousand EUR | -40.78% |
| 2013 Q2 | 282 Thousand EUR | 0.0% |
| 2013 Q4 | 167 Thousand EUR | 0.0% |
| 2013 Q1 | 282 Thousand EUR | 70.91% |
| 2012 Q3 | - EUR | -100.0% |
| 2012 Q4 | 165 Thousand EUR | 0.0% |
| 2012 FY | 165 Thousand EUR | -63.41% |
| 2012 Q2 | 273 Thousand EUR | 0.0% |
| 2011 Q2 | 766 Thousand EUR | 0.0% |
| 2011 FY | 451 Thousand EUR | -47.98% |
| 2011 Q4 | 451 Thousand EUR | 0.0% |
| 2010 Q2 | 851 Thousand EUR | 0.0% |
| 2010 FY | 867 Thousand EUR | -10.06% |
| 2010 Q4 | 867 Thousand EUR | 0.0% |
| 2009 Q2 | 1.49 Million EUR | 0.0% |
| 2009 FY | 964 Thousand EUR | -16.61% |
| 2009 Q4 | 964 Thousand EUR | 0.0% |
| 2008 FY | 1.15 Million EUR | -33.83% |
| 2008 Q4 | 1.15 Million EUR | 0.0% |
| 2007 FY | 1.74 Million EUR | -61.98% |
| 2006 FY | 4.59 Million EUR | 0.0% |
| 2005 FY | - EUR | 0.0% |
| 2004 FY | - EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -349.046% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 88.939% |
| Adocia SA | 4.54 Million EUR | -8.899% |
| Aelis Farma SA | 2.04 Million EUR | -141.406% |
| Biophytis S.A. | 3.11 Million EUR | -58.92% |
| Advicenne S.A. | 15.89 Million EUR | 68.898% |
| genOway Société anonyme | 5.51 Million EUR | 10.423% |
| IntegraGen SA | 642.28 Thousand EUR | -669.758% |
| Medesis Pharma S.A. | 1.2 Million EUR | -312.0% |
| Neovacs S.A. | 650 Thousand EUR | -660.615% |
| NFL Biosciences SA | 39.2 Thousand EUR | -12511.28% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -13.485% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -152.203% |
| Sensorion SA | 1.24 Million EUR | -298.417% |
| Theranexus Société Anonyme | 2.46 Million EUR | -100.917% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | -26.834% |
| TheraVet SA | 1 Million EUR | -394.104% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | 28.41% |
| argenx SE | 15.35 Million EUR | 67.8% |
| BioSenic S.A. | 15.57 Million EUR | 68.253% |
| Celyad Oncology SA | 902 Thousand EUR | -448.115% |
| DBV Technologies S.A. | 4.52 Million USD | -9.236% |
| Genfit S.A. | 62.25 Million EUR | 92.058% |
| GeNeuro SA | 6.49 Million EUR | 23.848% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -1337.209% |
| Innate Pharma S.A. | 30.6 Million EUR | 83.847% |
| Inventiva S.A. | 25.61 Million EUR | 80.7% |
| MaaT Pharma SA | 5.42 Million EUR | 8.866% |
| MedinCell S.A. | 52.8 Million EUR | 90.636% |
| Nanobiotix S.A. | 41.66 Million EUR | 88.133% |
| Onward Medical N.V. | 16.3 Million EUR | 69.68% |
| Oryzon Genomics S.A. | 3.45 Million EUR | -43.279% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | 86.076% |
| Oxurion NV | 117 Thousand EUR | -4125.641% |
| Pharming Group N.V. | 123.65 Million EUR | 96.002% |
| Poxel S.A. | 40.14 Million EUR | 87.684% |
| GenSight Biologics S.A. | 1.04 Million EUR | -371.756% |
| Transgene SA | 17 Thousand EUR | -28982.353% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 99.828% |
| Valneva SE | 132.76 Million EUR | 96.276% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |